Compare
Calidi Biotherapeutics, Inc. vs Creative Medical Technology Holdings, Inc. vs VivoSim Labs, Inc. vs Scinai Immunotherapeutics Ltd.
| Latest fiscal year | Calidi Biotherapeutics, Inc. CLDI | Creative Medical Technology Holdings, Inc. CELZ | VivoSim Labs, Inc. VIVS | Scinai Immunotherapeutics Ltd. SCNI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | n/a | $6.0K | $131.0K | $1.31M |
| Revenue growth (YoY) | n/a | -45.5% | -9.0% | +99.2% |
| Gross margin | n/a | 63.4% | n/a | -202.3% |
| Operating margin | n/a | n/m | n/m | -575.3% |
| Net margin | n/a | n/m | n/m | -633.6% |
| Net income | -$19.91M | -$6.00M | -$13.84M | -$8.31M |
| EPS (Diluted) | -$5.95 | -$2.52 | -$5.35 | n/a |
| Operating cash flow | -$21.29M | -$5.86M | -$10.83M | -$6.03M |
| Free cash flow | n/a | n/a | -$10.83M | -$6.05M |
| Cash & equivalents | n/a | n/a | $5.02M | $1.66M |
| Total assets | $8.86M | $7.81M | $7.39M | $11.63M |
| Total liabilities | $5.10M | $284.9K | $8.48M | n/a |
| Shareholders' equity | $3.76M | $7.51M | -$1.10M | $8.10M |
| Return on year-end equity | -529.6% | -79.8% | n/a | -102.5% |
| Shares outstanding | 7.22M | 3.70M | 2.89M | 13.87B |
Revenue, most recent five fiscal years
| Fiscal year | Calidi Biotherapeutics, Inc. | Creative Medical Technology Holdings, Inc. | VivoSim Labs, Inc. | Scinai Immunotherapeutics Ltd. |
|---|---|---|---|---|
| Latest | $45.0K Ended 2022-12-31 | $6.0K Ended 2025-12-31 | $131.0K Ended 2026-03-31 | $1.31M Ended 2025-12-31 |
| 1 year earlier | n/a | $11.0K Ended 2024-12-31 | $144.0K Ended 2025-03-31 | $658.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $9.0K Ended 2023-12-31 | $109.0K Ended 2024-03-31 | n/a |
| 3 years earlier | n/a | $88.6K Ended 2022-12-31 | $370.0K Ended 2023-03-31 | n/a |
| 4 years earlier | n/a | $87.8K Ended 2021-12-31 | $1.50M Ended 2022-03-31 | n/a |